Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Pr

Published

on

<!– Name:DistributionId Value:8811131 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:23c65b22-4094-4d2f-b1b6-e261dc18703b –>

New York, USA, April 20, 2023 (GLOBE NEWSWIRE) — Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Propel Market

The neuroblastoma market is expected to surge in the coming years in the seven major markets owing to the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate.

DelveInsight’s Neuroblastoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroblastoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Neuroblastoma Market Report

Advertisement
Stake.com
  • As per DelveInsight analysis, the neuroblastoma market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • According to DelveInsight analysis, it was found that neuroblastoma affects males slightly more than females.
  • Leading neuroblastoma companies such as Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals LLC, Jubilant DraxImage Inc., Curis, Inc., Valent Technologies, LLC, Elicio Therapeutics, Cellectar Biosciences, Inc., Pfizer, Hoffmann-La Roche, Endeavor Biomedicines, Inc., and others are developing novel neuroblastoma drugs that can be available in the neuroblastoma market in the coming years.
  • Some of the key therapies for neuroblastoma treatment include Omburtamab, SARTATE, Eflornithine, Cabozantinib, LY3295668 Erbumine, 18F-MFBG, 131-MIBG + Vorinostat, CUDC-907, VAL-413, DFMO + Bortezomib, ELI-002 7P, CLR 131, Lorlatinib, Crizotinib, Entrectinib, ENV-101 (taladegib), and others.
  • Several neuroblastoma therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major neuroblastoma market share @ Neuroblastoma Market Report

Neuroblastoma Overview

Neuroblastoma is an embryonic cancer of the sympathetic nervous system that develops from neuroblasts. It is taken from two words: “neuro” signifies nerves, and “blastoma” is a tumor that affects immature or developing cells. It is caused by sympathetic nervous system tissue in the adrenal medulla and paraspinal or periaortic areas. Neuroblastoma is occasionally caused by a gene mutation (change) handed down from parent to child. Children with specific gene mutations or genetic diseases should be monitored for neuroblastoma symptoms until they reach age 10.

Neuroblastoma symptoms can include abdominal mass, which can be felt during an examination or seen as a large abdomen, dark circles around the eyes, unexplained fevers, persistent diarrhea, bone pain, weight loss, weariness, and many others. Neuroblastoma frequently spreads to bone marrow. If catecholamine levels in the blood or urine are elevated, identifying cancer cells in a bone marrow sample is sufficient for neuroblastoma diagnosis. 

Neuroblastoma Epidemiology Segmentation

As per the DelveInsight estimates, the United States has the highest incident population of neuroblastoma.

Advertisement
Stake.com

The neuroblastoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Cases of Neuroblastoma
  • Gender-specific Incident Cases of Neuroblastoma
  • Age-specific Incident Cases of Neuroblastoma
  • Incident Patient Population of Neuroblastoma by Risk Groups

Download the report to understand which factors are driving neuroblastoma epidemiology trends @ Neuroblastoma Epidemiological Insights

Neuroblastoma Treatment Market 

Neuroblastoma patients might get a variety of treatments. Some neuroblastoma treatments are mainstream, while others are being investigated in clinical studies. A child’s risk category mostly determines neuroblastoma treatment. There are four standard risk groups: low risk, middle risk, high risk, and recurrent neuroblastoma. In general, younger children with smaller tumors are in the lower-risk groups, while older children, children with tumors that have spread throughout the body, and children whose tumors exhibit unfavorable traits or additional copies of the MYCN gene are in the high-risk group. Some infants with neuroblastoma that have progressed throughout the body may still be considered low risk, particularly if their tumor lacks additional copies of MYCN or other unfavorable characteristics.

Surgery is the first step in treatment for neuroblastoma patients in the low and intermediate-risk groups, followed by chemotherapies, radiation, and retinoid therapies (isotretinoin). Radiation and retinoid treatments are only utilized in intermediate-risk patients. In high-risk neuroblastoma patients, the discussed medicines, coupled with stem cell transplantation and immunotherapies (Qarziba and Unituxin), are also recommended. 

To know more about neuroblastoma treatment, visit @ Neuroblastoma Treatment Drugs 

Advertisement
Stake.com

Key Neuroblastoma Therapies and Companies

  • Omburtamab: Y-mabs therapeutics
  • SARTATE: Clarity Pharmaceuticals
  • Eflornithine: K C Pharmaceuticals
  • Cabozantinib: Exelixis
  • LY3295668 Erbumine: Eli Lilly and Company
  • 18F-MFBG: Innervate Radiopharmaceuticals LLC
  • 131-MIBG + Vorinostat: Jubilant DraxImage Inc.
  • CUDC-907: Curis, Inc.
  • VAL-413: Valent Technologies, LLC
  • DFMO + Bortezomib: K C Pharmaceuticals Inc.
  • ELI-002 7P: Elicio Therapeutics
  • CLR 131: Cellectar Biosciences, Inc.
  • Lorlatinib: Pfizer
  • Crizotinib: Pfizer
  • Entrectinib: Hoffmann-La Roche
  • ENV-101 (taladegib): Endeavor Biomedicines, Inc.

Learn more about the FDA-approved drugs for neuroblastoma @ Drugs for Neuroblastoma Treatment 

Neuroblastoma Market Dynamics

The dynamics of the neuroblastoma market are anticipated to change in the coming years. The neuroblast may be caused by immature cell development or a mutation in the gene that controls cell proliferation. more juvenile cancer cases, more research on neuroblastoma treatment, and increased cancer treatment spending will likely fuel neuroblastoma market expansion over the forecast period. Moreover, as our understanding of neuroblastoma biology grows, so are our methods of treating the disease. Improved risk stratification and the use of predictive biomarkers will aid in therapy selection for patients with neuroblastoma, and future medicines are likely to have higher efficacy and lower toxicity, thus propelling the neuroblastoma market growth. Furthermore, the neuroblastoma pipeline is highly robust; many possible therapies are being studied for neuroblastoma treatment, and it is safe to assume that the therapeutic space will substantially impact the neuroblastoma market throughout the forecast period.

However, certain factors may affect the growth of the neuroblastoma market. Neuroblastoma can be almost benign in some children, with spontaneous regression, but most older individuals have a high-risk illness that is usually deadly, despite the finest current treatments. Moreover, the neuroblastoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the neuroblastoma market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Neuroblastoma Companies Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals LLC, Jubilant DraxImage Inc., Curis, Inc., Valent Technologies, LLC, Elicio Therapeutics, Cellectar Biosciences, Inc., Pfizer, Hoffmann-La Roche, Endeavor Biomedicines, Inc., and others
Key Neuroblastoma Therapies Omburtamab, SARTATE, Eflornithine, Cabozantinib, LY3295668 Erbumine, 18F-MFBG, 131-MIBG + Vorinostat, CUDC-907, VAL-413, DFMO + Bortezomib, ELI-002 7P, CLR 131, Lorlatinib, Crizotinib, Entrectinib, ENV-101 (taladegib), and others

Scope of the Neuroblastoma Market Report

Advertisement
Stake.com
  • Therapeutic Assessment: Neuroblastoma current marketed and emerging therapies
  • Neuroblastoma Market Dynamics: Attribute Analysis of Emerging Neuroblastoma drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Neuroblastoma Market Access and Reimbursement

Discover more about neuroblastoma drugs in development @ Neuroblastoma Clinical Trials

Table of Contents

1. Neuroblastoma Market Key Insights
2. Neuroblastoma Market Report Introduction
3. Neuroblastoma Market Overview at a Glance
4. Neuroblastoma Market Executive Summary
5. Disease Background and Overview
6. Neuroblastoma Treatment and Management
7. Neuroblastoma Epidemiology and Patient Population
8. Patient Journey
9. Neuroblastoma Marketed Drugs
10. Neuroblastoma Emerging Drugs
11. Seven Major Neuroblastoma Market Analysis
12. Neuroblastoma Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Neuroblastoma Market Drivers
16. Neuroblastoma Market Barriers
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Related Reports

Neuroblastoma Pipeline

Neuroblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroblastoma companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.

Neuroblastoma Epidemiology Forecast

Advertisement
Stake.com

Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pediatric Neuroblastoma Pipeline

Pediatric Neuroblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pediatric neuroblastoma companies, including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.

Pediatric Neuroblastoma Market

Pediatric Neuroblastoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric neuroblastoma companies including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.

Advertisement
Stake.com

Pediatric Neuroblastoma Epidemiology

Pediatric Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted pediatric neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Neuroblastoma Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Advertisement
Stake.com

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Advertisement
Stake.com

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Baxter Planning Wins AI-based SupplyTech Solution of the Year Award 2024

Published

on

baxter-planning-wins-ai-based-supplytech-solution-of-the-year-award-2024

AUSTIN, Texas, June 13, 2024 /PRNewswire/ — Baxter Planning, the leading provider of Service Supply Chain technology, has been selected as a winner of the AI-based SupplyTech Solution of the Year award for its predictive Service Supply Chain platform, BaxterPredict. The SupplyTech Breakthrough Awards recognize and evaluate the most innovative solutions, services, and companies in the rapidly evolving supply chain space. In 2024 there were thousands of nominations from across the globe.

“We are thrilled to have been awarded the 2024 SupplyTech Breakthrough Award for AI-based SupplyTech Solution of the Year,” stated Chad Hawkinson, Chief Product Officer of Baxter Planning. “Our customers have driven us to make the hype of AI a reality in spare parts management. With our BaxterPredict platform, and specifically our Prophet.ai module, we are applying AI to solve real problems for our customers and the feedback from them has been incredibly positive. Baxter Planning is in the business of helping our customers make predictions, specifically about spare parts demand. By embracing AI, we have found even more powerful ways to save our customers significant money while also improving their ability to meet their own customer’s needs.”
Integration of AI and automation in the Service Supply Chain is crucial for service organizations to maintain competitiveness and meet heightened customer expectations. The BaxterPredict platform enables companies to optimize operations, enhance efficiency, and improve accuracy in demand forecasting and inventory management.
One aspect of BaxterPredict is its new AI-enabled module, Prophet.ai. This new module utilizes AI to eliminate the guesswork associated with New Product Introduction (NPI) and Last-Time-Buy (LTB) decisions for Service Supply Chains, saving them significantly.
As the industry faces increasing pressure to provide better service at lower costs, embracing these innovations is essential for sustaining growth and achieving operational excellence.
The Baxter Planning team has been dedicated to partnering with its Service Supply Chain customers and has found real value and opportunity with the judicial application of AI into its already best-of-breed products. The company plans to invest further in AI for a variety of use cases to truly optimize Service Supply Chains.
Learn more at baxterplanning.com.
About Baxter Planning
Baxter Planning is the world leader in Service Supply Chain technology. Global customers with even the most complex service operations trust our team to help them set the spare parts plan, manage the order execution, and streamline escalation management.
The company’s end-to-end predictive platform, BaxterPredict, transforms Service Supply Chains using best practices, AI/ML, and domain expertise to drive cost reduction, increase resiliency, refine optimization, and enable end-to-end visibility control. Baxter Planning customers see reduced spend in inventory, logistics, and operations while increasing their customer satisfaction. Headquartered in Austin, Texas, Baxter Planning is used by some of the largest global high-tech, healthcare, commercial, and industrial OEM businesses.
Baxter Planning is a portfolio company of Marlin Equity Partners, a global investment firm with approximately $9 billion in capital commitments. The firm is headquartered in Los Angeles, California with an additional office in London. For more information, please visit www.marlinequity.com.
Logo – https://mma.prnewswire.com/media/2210358/BP_BaxterPredict_CMYK_Lockup_Stacked_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/baxter-planning-wins-ai-based-supplytech-solution-of-the-year-award-2024-302172251.html

Continue Reading

Artificial Intelligence

AI Development Accelerates: Market Watch on Emerging AI Innovations

Published

on

ai-development-accelerates:-market-watch-on-emerging-ai-innovations

USA News Group CommentaryIssued on behalf of Scope AI Corp.
VANCOUVER, BC, June 13, 2024 /PRNewswire/ — The future of artificial intelligence (AI) is unfolding before our eyes. Actions made today will undoubtedly pave the way for the AI road ahead, with calls for more AI regulation, energy and grid security, and AI employee protections. All the while, investment in AI is surging, with Generative AI Venture Capital Investment on track to reach $12 billion in 2024, according to analysts at EY. Meanwhile McKinsey is predicting that generative AI alone could generate $2.6 trillion to $4.4 trillion in value across industries. This is why the market is keen on monitoring the advancements of AI developers, including Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF), Meta Platforms, Inc. (NASDAQ: META), Alphabet Inc. (NASDAQ: GOOG, GOOGL), Microsoft Corporation (NASDAQ: MSFT), and Amazon.com, Inc. (NASDAQ: AMZN).

With rapid advancements in deep machine learning, Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF) has rebranded and shifted its market focus. The company is now directing its state-of-the-art GEM (General Enterprise Machine Learning) technology towards crucial sectors such as advertising, gaming, and neural networks.
Their ongoing development of GEM is working toward enabling businesses to create custom object detection and visual information systems, harnessing the full potential of neural networks. Scope AI’s strategic efforts aim to transform the fields of advertising personalization, gaming enhancements, and the various applications of neural networks.
Recently, Scope AI has unveiled significant enhancements to GEM, aimed at improving services for advertising agencies and the gaming sector. These upgrades allow GEM to refine advertising content and boost gameplay experiences with sophisticated neural network features. The improvements also strengthen the platform’s object visual recognition capabilities, enabling businesses to gain more profound insights and deploy more accurate solutions. With better object detection and visual information systems, advertisers can more effectively analyze consumer behavior and optimize their campaigns, while game developers can craft more engaging and immersive user experiences.
“We’re very pleased at how seamless we were able to streamline, enhance, and strengthen our platform with the latest performance and security upgrades made to our infrastructure,” said Sean Prescott, Founder and Non-Executive Chairman of Scope. “The next generation of our platform will set us apart in what kind of data and its sensitivity we can process and store. It’s a potential game-changer for the industry.”
Scope AI has introduced significant upgrades to their GEM platform, aiming to revolutionize the advertising and gaming industries with new advanced features and deeper insights. The intuitive web interface of GEM allows users—from developers to large enterprises—to easily implement sophisticated object detection systems and develop real-time neural network models.
In the advertising sector, GEM’s enhanced visual recognition technology facilitates the creation of highly targeted and engaging advertisements. This advancement leads to more efficient ad spending and higher customer engagement levels, transforming how ads are crafted and delivered.
For the gaming industry, Scope AI’s GEM platform is set to redefine player experiences. By analyzing player behavior through neural networks, GEM customizes gameplay and recommendations, providing developers with critical insights to improve game design, enhance player retention, and generate new revenue streams. These upgrades position GEM as a crucial tool for both industries, offering innovative solutions and driving forward technological progress.
In what seems to be a controversial move, Meta Platforms, Inc. (NASDAQ: META) is reportedly set to use social media posts from Europe to train its Llama large language models. In an interview with Reuters, Meta’s top policy executive said that the company uses public Facebook and Instagram posts to train its Llama models, while excluding private posts and messages shared only with friends.
Also noteworthy, is a CNBC report that claims an investment firm called IFiAI that uses IBM’s Watsonx to help make projections about the short-term directions of stocks, has predicted big upside in Meta Platforms in the coming month. One of the new announcements already shared this month, is the plan for Meta to introduce free AI chatbots on its popular WhatsApp messenger platform.
“They need to find a way to show investors with some degree of conviction that there is a there there,” said Mark Shmulik, an analyst for Bernstein. “An AI-powered chatbot inside of business messaging feels like a great place to deploy it. You might be able to find product market fit sooner than you will on smart glasses.”
Google parent Alphabet Inc. (NASDAQ: GOOG, GOOGL) launched a flurry of announcements in May that demonstrated the tech giant’s ambitions to beef up its AI search and chatbot options. Google’s latest innovations include the addition of Flash to its Gemini 1.5 AI model family, designed to be faster and more cost-effective. Another breakthrough is Project Astra, a prototype capable of conversing with users about anything their smartphone camera captures in real time. Additionally, Google has introduced search results organized under AI-generated headlines.
“This is a moment of growth and opportunity,” said Sundar Pichai, CEO of Alphabet, when asked if the AI updates could risk Google’s profitable business.
Additionally, Google is introducing AI Overviews to all U.S. users for its search function this week, following extensive public testing since last year’s I/O event. This feature leverages generative AI to compile information and address more complex queries that lack straightforward answers on the web.
“The AI Overviews launch reception this week will be an indicator of how well Google can adapt its Search product to meet the demands of the generative AI era,” said Jacob Bourne, analyst of eMarketer. “To maintain its competitive edge and satisfy investors, Google will need to focus on translating its AI innovations into profitable products and services at scale.”
After an outcry regarding privacy concerns, Microsoft Corporation (NASDAQ: MSFT) recently backtracked on a plan to have its new AI-powered PCs utilize a “Recall” feature that would capture and store screenshots of users’ desktop activities. Moving on from the controversy, it appears Microsoft is now considering a big new software bundle plan to monetize AI features in its popular productivity software suite Microsoft 365, according to sources as reported by Business Insider.
Meanwhile, the market is paying close attention to an ongoing investigation by the Federal Trade Commission (FTC) regarding a deal with AI startup Inflection. The FTC is investigating whether Microsoft’s investment in Inflection should have been classified as an acquisition that the company failed to disclose to the government, according to a source reported by CNN.
“Our agreements with Inflection gave us the opportunity to recruit individuals at Inflection AI and build a team capable of accelerating Microsoft Copilot, while enabling Inflection to continue pursuing its independent business and ambition as an AI studio,” said a Microsoft spokesperson in a statement to CNN, adding that the company is “confident” it has complied with its reporting obligations.
For eCommerce and data center giant Amazon.com, Inc. (NASDAQ: AMZN), its subsidiary Amazon CloudWatch recently announced the general availability of natural language query generation powered by generative AI for Logs Insights and Metrics Insights. This feature allows users to effortlessly create queries within the context of their logs and metrics data using plain language. By streamlining the query generation process, it enables the user to quickly derive insights from observability data without requiring deep knowledge of the query language.
Amazon’s subsidiary Amazon Web Services (AWS) also recently debuted 2 new AI certifications to train more people and give them an edge in the pursuit of the growing number of in-demand cloud jobs. The AWS certifications include the AWS Certified AI Practitioner foundation-level certification, and the AWS Certified Machine Learning Engineer – Associate certification for individuals with at least a year of experience building, deploying, and maintaining AI and ML solutions on AWS. To date, AWS provides over 100 courses and learning resources in AI, ML, and generative AI through AWS Skill Builder and AWS Educate, equipping learners for the future of work.
Article Source: https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/ 
CONTACT:
USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Scope AI Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares Scope AI Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Scope AI Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Scope AI Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/ai-development-accelerates-market-watch-on-emerging-ai-innovations-302172161.html

Continue Reading

Artificial Intelligence

SciBase welcomes new chairman and thanks the former

Published

on

scibase-welcomes-new-chairman-and-thanks-the-former

STOCKHOLM, June 13, 2024 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.

We are pleased to announce the election of Jesper Høiland as the new Chairman of the Board. Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product launches and infrastructure building). Jesper has lived and worked in the US, Switzerland, Denmark, Australia, France, Belgium and Canada for the past 30 years. 
“We are happy about the election of Jesper Høiland as the new Chairman of our board,” says Pia Renaudin CEO of SciBase. “He will bring valuable insights and experience especially from the US market, which is our primary focus. We also welcome, as previously communicated, Robert Molander as new member of the Board.”
In addition, we would like to extend our gratitude to Tord Lendau for his commitment and invaluable contributions during his lead as Chairman of the Board. Tord has been a member of the board since 2014. During this time SciBase has made significant progress in navigating challenging regulatory processes and market environments and has reached profitability in Germany through growing sales of Nevisense and electrodes. Nevisense remains the only melanoma detection product approved in the US. The foundation for further growth has been laid.
“We extend our deepest thanks to Tord for his exceptional leadership and commitment to SciBase,” says Pia Renaudin. “He has been instrumental in SciBase progress. I also want to take the opportunity to thank both Dr Matt Leavitt and Jvalini Dwarkasing for their support in driving SciBase forward as they now retire as members of the Board.”
SciBase is excited about the future and remains committed to become the standard of Care in the areas we work in. We look forward to achieving new milestones and providing our AI driven technology to clinicians so they can improve and save lives through timely detection and intervention at the first signs of skin diseases and to reduce healthcare costs.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected] Advisor (CA):Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases 
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/scibase/r/scibase-welcomes-new-chairman-and-thanks-the-former,c4000649
The following files are available for download:
https://mb.cision.com/Main/12371/4000649/2864256.pdf
PM_new CoB final
 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-welcomes-new-chairman-and-thanks-the-former-302172126.html

Continue Reading

Trending